NCT01475279View on ClinicalTrials.gov

A Study to Evaluate the Effect of T89(Dantonic®)on Steady-State Pharmacodynamics of Warfarin

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

July 31, 2011

Primary Completion Date

November 30, 2011

Study Completion Date

January 31, 2012

Conditions
Healthy
Interventions
DRUG

Warfarin; Dantonic

Individual warfarin dose during the study; 225mg Dantonic b.i.d for one week

Trial Locations (1)

78209

Healthcare Discoveries, LLC d/b/a ICON Development Solutions, San Antonio

All Listed Sponsors
lead

Tasly Pharmaceuticals, Inc.

INDUSTRY

NCT01475279 - A Study to Evaluate the Effect of T89(Dantonic®)on Steady-State Pharmacodynamics of Warfarin | Biotech Hunter | Biotech Hunter